SecBot SecBot

ZYME

Zymeworks Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001937653 Biotech & Drug Discovery
$26.24 −0.23 (−0.87%)
Nov 13 4:00 PM ET · prev $26.47
Market cap
$1.8B
Small cap
Consensus
Buy
95% Buy or better · 19 analysts
Median target
$41.50
+58% · range $35.00–60.00
1 year
+9.8%
from $23.90 · Nov 17
30 days
+2.7%
from $25.54
52-week range
$21.81–31.46
−17% from high · low Aug 3
Avg volume 20D
1.38M
shares / day
Short interest
5.91M
≈8.4% of shares · +6.0%
Days to cover
4.3
at average volume
Insider net
−$357.6K
12 mo · excl. 3 subscriber-only trades
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
15
analyzed by SecBot
SecBot read BULLISH 14 reports · 90 days
Balance 0 bearish · 5 bullish · 9 neutral oldest → newest, height = score
Avg score ·High conf. 10/14

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersMIXED

    1 insider sold $357.6K. Excludes 3 subscriber-only trades.

  • InstitutionsMIXED

    Q3 2026: 20 added (0 new), 14 trimmed or exited.

  • AnalystsBULLISH

    18 of 19 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate $2.100 → $2.185 over 90 days. 2 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest +6.0% to 5.91M shares. 4.3 days to cover, ≈8.4% of shares.

  • TrendRANGE

    4% below its 50-day average. New closing high $31.46 on Nov 10.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
MORGAN STANLEYADD3,236,915$85.7M
Fisher Asset Management, LLCDOUBLED608,612$16.1M
DIMENSIONAL FUND ADVISORS LPTRIM530,448$14.1M
FEDERATED HERMES, INC.ADD246,979$6.5M
Jump Financial, LLCDOUBLED230,236$6.1M
FMR LLCTRIM230,164$6.1M
FRANKLIN TEMPLETON INCDOUBLED169,778$5.3M
Pictet Asset Management Holding SATRIM188,468$5.1M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

19 analysts
Buy 95% rate it Buy or better
Strong Buy7Buy11Hold1Sell0Strong Sell0
12-month targets · 14 analysts

Price is below the lowest target. Median implies +58%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 13, 2026Citizens
MAINTAIN
MAINTAINMarket Outperform
Nov 11, 2026Citigroup
MAINTAIN
MAINTAINBuy
Nov 10, 2026TD Cowen
MAINTAIN
MAINTAINBuy
Nov 10, 2026Truist Securities
MAINTAIN
MAINTAINBuy
Nov 10, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Oct 28, 2026Truist Securities
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$357.6K
sold · 1 insider · excl. 3 subscriber-only trades
DateInsiderTypeValue
Nov 13, 2026🔒 Fresh data, subscribers only
Nov 13, 2026
SELL
Nov 13, 2026🔒 Fresh data, subscribers only
Nov 13, 2026
SELL
Nov 13, 2026🔒 Fresh data, subscribers only
Nov 13, 2026
SELL
Nov 13, 2026🔒 Fresh data, subscribers only
Nov 13, 2026
EXERCISE
Oct 9, 2026
Schayowitz Adam
EVP, Head of R&D
Oct 9, 2026
EXERCISE37,037 sh
Oct 9, 2026
Schayowitz Adam
EVP, Head of R&D
Oct 9, 2026
SELL$357.6K
Jul 6, 2026
Hollywood Mark
EVP & Chief Operating Officer
Jul 6, 2026
AWARD$20.9K
May 13, 2026
Schneider Paul R
EVP, General Counsel
May 13, 2026
AWARD178,000 sh

Earnings setup

Estimates
$2.19
EPS estimate, this quarter
+4%
estimate change, 90 days
2↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q$2.19-$0.57–$3.29-4.5%$77.9M
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
5,914,601
shares short
+6.0%
vs prior settlement
4.3
days to cover
≈8.4%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 Press
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 Buyback
🔒 Fresh data, subscribers only
Nov 13, 2026 SEC
Paul Andrew Moore, an officer of Zymeworks, filed a Form 144 notice of intent to sell 39,741 shares of common stock…
144 · Impact 2/10
Nov 13, 2026 Insider
🔒 Fresh data, subscribers only
Nov 13, 2026 Insider
🔒 Fresh data, subscribers only
Nov 13, 2026 Insider
🔒 Fresh data, subscribers only
Nov 9, 2026 SEC
This 8-K/A amends the original 8-K to provide historical financial statements of Theravance Biopharma and unaudited…
8-K/A · Impact 5/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
4 drugs tracked · Drug pipeline →
Recent
Nov 16, 2026
Buyback
🔒 Fresh data, subscribers only
Nov 9, 2026
Earnings
Zymeworks Provides Corporate Update and Reports Third Quarter 2026 Financial Results
VANCOUVER, British Columbia, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of…
Nov 9, 2026
Earnings result
ZYME Q3 2026 Earnings: EPS $2.28 (-1.9% vs est)
Oct 24, 2026
Press release
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
ZW191 demonstrates compelling anti-tumor activity in heavily pretreated patients with platinum-resistant ovarian cancer across folate receptor alpha…
Oct 19, 2026
Press release
Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma
VANCOUVER, British Columbia , Oct. 19, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of…

SecBot reports

15 filings · 10 press releases · 3 bullish · 0 bearish · 12 neutral
All ZYME filing & press-release reports (25)